Trials in Long Beach, California
Here are the top 10 medical studies for breast cancer in Long Beach, California
Popular Filters
Phase 3 Trials
Antibody-Drug Conjugate
Dato-DXd for Breast Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a new drug called datopotamab deruxtecan to see if it helps patients with advanced breast cancer live longer or have a better quality of life compared to standard chemotherapy. Datopotamab deruxtecan has shown encouraging response rates and manageable toxicity in patients with advanced/metastatic triple-negative breast cancer.
CDK4/6 Inhibitor
Abemaciclib + Fulvestrant for Breast Cancer
Recruiting1 awardPhase 3
Los Alamitos, California
This trial is testing a combination of two drugs, abemaciclib and fulvestrant, for treating a specific type of breast cancer that has not responded to previous treatments. Abemaciclib is taken orally and is approved for treating certain types of breast cancer. The goal is to see if this combination can help stop the cancer from growing. The study may last several years, depending on how well the treatment works for each patient.
Small Molecule Kinase Inhibitor
Tucatinib + Trastuzumab + Pertuzumab for Breast Cancer
Recruiting1 awardPhase 3
Torrance, California
This trial is testing to see if adding tucatinib to trastuzumab and pertuzumab will help people with HER2-positive breast cancer live longer without their disease getting worse.
Selective Estrogen Receptor Degrader (SERD)
Giredestrant + Everolimus for Advanced or Metastatic Breast Cancer
Recruiting2 awardsPhase 3
Cerritos, California
This trial is testing if a combination of giredestrant and everolimus works better than other hormone treatments plus everolimus in patients with advanced breast cancer who have already tried other treatments. The drugs work by blocking estrogen receptors and a growth pathway in cancer cells. Everolimus has been shown to improve outcomes in breast cancer patients when combined with hormonal treatments.
Selective Estrogen Receptor Degrader (SERD)
Giredestrant + Phesgo for Breast Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing whether a combination of two drugs is more effective than one drug for patients with advanced breast cancer. The drugs work by blocking signals that help cancer cells grow. The study focuses on patients whose cancer cannot be cured with surgery or other local treatments.
Trials With No Placebo
Behavioral Intervention
Virtual Group-Based Physical Activity for Cancer Survivors
Recruiting1 award8 criteria
Los Angeles, California
This trial will test whether group-based physical activity, delivered virtually, is feasible for AYA cancer survivors who have completed treatment. 20 participants will be enrolled for 3 months.
Chemotherapy
AZD8205 for Endometrial Cancer
Recruiting1 awardPhase 1 & 2
Santa Monica, California
This trial is testing a new drug called AZD8205 to see if it can help treat advanced or spreading solid tumors. The study includes patients whose cancer is advanced or has spread and may not respond to current treatments. AZD8205 might work by stopping or slowing down the growth of cancer cells.
Chemotherapy
NX-1607 for Advanced Cancer
Recruiting1 awardPhase 1
Los Angeles, California
This trial is testing NX-1607, a new experimental drug, in adults with advanced cancers that don't respond to standard treatments. The goal is to see if NX-1607 can safely stop or reduce cancer growth, either by itself or with another drug called paclitaxel. Paclitaxel is a widely used anti-cancer drug for treating various types of solid malignant tumors including breast, ovarian, and lung cancers.
Antibody-Drug Conjugate
Dato-DXd for Breast Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing a new drug called datopotamab deruxtecan to see if it helps patients with advanced breast cancer live longer or have a better quality of life compared to standard chemotherapy. Datopotamab deruxtecan has shown encouraging response rates and manageable toxicity in patients with advanced/metastatic triple-negative breast cancer.
Tyrosine Kinase Inhibitor
BAY2927088 for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Duarte, California
This trial is testing a new drug called BAY2927088 for people with advanced lung cancer. The drug aims to block certain proteins that help cancer grow. Researchers want to find out how safe the drug is, the best dose to use, and how well it works in stopping cancer.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.